Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Relypsa IIb Hits Primary Endpoint | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Relypsa IIb Hits Primary Endpoint

Patiromer reduces potassium over time

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Relypsa has reported that the Phase IIb trial studying the safety and efficacy of patiromer as a treatment for hyperkalemia has met its primary efficacy endpoint of significant mean change of serum potassium by week four.

Additionally, treatment with patiromer maintained mean serum potassium within the normal range for up to one year, supporting persistence of the potassium lowering effect of patiromer over time. These clinically meaningful results provide supportive evidence for the efficacy, safety and tolerability of patiromer as a treatment for hyperkalemia when dosed twice daily over the long-term. Patiromer was well tolerated in this trial when dosed twice daily for up to one year.

The Phase IIb trial was an open-label, randomized, dose ranging trial to determine the optimal starting dose(s) and the efficacy and safety of patiromer when used over the long-term to treat hyperkalemia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics